For more information on this analysis, please click on here.

“Tech companies’ partnerships and horizontal integration with life sciences companies have laid the foundation for rapid and cost-effective drug discovery and development,” said Surbhi GuptaSenior Healthcare and Life Sciences Industry Analyst. “Additionally, all major genomics technology companies are channeling their resources to digitize genomics data to better select patients for clinical trials and reduce clinical study turnaround time.”

Gupta added, “Due to the increasing use of machine learning and artificial intelligence in personalized medicine, the pharmaceutical industry will shift from a symptom-based to a genetics-based approach to treatment. Additionally, precision medicine can offer detailed insights into cellular and molecular alterations, accelerating the development of targeted therapies. »

Digitization and innovation in the pharmaceutical industry will open up new growth opportunities, including:

• Digital therapy companies must excel in areas where many pharmaceutical companies fall short, including data analytics, interoperability, user-centric design, and flexible business models.
• Innovative formulation and delivery technologies that improve the stability of RNA at room temperature will facilitate rapid global adoption of RNA-based therapies at reduced costs.
• Development and contract manufacturing companies should partner with global enterprises to meet the required clinical drug manufacturing experience and expand market reach in Asia Pacific.

Global Pharmaceuticals Outlook, 2022 is the latest addition to Frost & Sullivan’s Health and life sciences research and analysis available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous stream of growth opportunities to succeed in the unpredictable future.

About Frost & Sullivan

For six decades, Frost & Sullivan has been recognized globally for its role in helping investors, business leaders and governments navigate economic change and identify disruptive technologies, megatrends, new business models and businesses into action, driving a steady stream of growth. opportunities to foster future success. Contact us: Start the discussion

Global Pharmaceuticals Outlook, 2022

CCP8

Contact:
maria Celeste Bailo
Business communication
E : [email protected]

SOURCE Frost & Sullivan